Abstract
Galectins comprise a family of animal lectins that differ in their affinity for β-galactosides. Galectin-9 (Gal-9) is a tandem-repeat-type galectin that was recently shown to function as a ligand for T-cell immunoglobin domain and mucin domain-3 (Tim-3) expressed on terminally differentiated CD4+ Th1 cells. Gal-9 modulates immune reactions, including the induction of apoptosis in Th1 cells. In this study, we investigated the effects of Gal-9 in murine models of acute GVH disease (aGVHD). First, we demonstrated that recombinant human Gal-9 inhibit MLR in a dose-dependent manner, involving both Ca2+ influx and apoptosis in T cells. Next, we revealed that recombinant human Gal-9 significantly inhibit the progression of aGVHD in murine BM transplantation models. In conclusion, Gal-9 ameliorates aGVHD, possibly by inducing T-cell apoptosis, suggesting that gal-9 may be an attractive candidate for the treatment of aGVHD.
| Original language | English |
|---|---|
| Pages (from-to) | 67-75 |
| Number of pages | 9 |
| Journal | European Journal of Immunology |
| Volume | 41 |
| Issue number | 1 |
| DOIs | |
| Publication status | Published - Jan 1 2011 |
| Externally published | Yes |
Fingerprint
All Science Journal Classification (ASJC) codes
- Immunology and Allergy
- Immunology
Cite this
Galectin-9 ameliorates acute GVH disease through the induction of T-cell apoptosis. / Sakai, Kazuki; Kawata, Eri; Ashihara, Eishi; Nakagawa, Yoko; Yamauchi, Akira; Yao, Hisayuki; Nagao, Rina; Tanaka, Ruriko; Yokota, Asumi; Takeuchi, Miki; Hirai, Hideyo; Kimura, Shinya; Hirashima, Mitsuomi; Yoshimura, Norio; Maekawa, Taira.
In: European Journal of Immunology, Vol. 41, No. 1, 01.01.2011, p. 67-75.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Galectin-9 ameliorates acute GVH disease through the induction of T-cell apoptosis
AU - Sakai, Kazuki
AU - Kawata, Eri
AU - Ashihara, Eishi
AU - Nakagawa, Yoko
AU - Yamauchi, Akira
AU - Yao, Hisayuki
AU - Nagao, Rina
AU - Tanaka, Ruriko
AU - Yokota, Asumi
AU - Takeuchi, Miki
AU - Hirai, Hideyo
AU - Kimura, Shinya
AU - Hirashima, Mitsuomi
AU - Yoshimura, Norio
AU - Maekawa, Taira
PY - 2011/1/1
Y1 - 2011/1/1
N2 - Galectins comprise a family of animal lectins that differ in their affinity for β-galactosides. Galectin-9 (Gal-9) is a tandem-repeat-type galectin that was recently shown to function as a ligand for T-cell immunoglobin domain and mucin domain-3 (Tim-3) expressed on terminally differentiated CD4+ Th1 cells. Gal-9 modulates immune reactions, including the induction of apoptosis in Th1 cells. In this study, we investigated the effects of Gal-9 in murine models of acute GVH disease (aGVHD). First, we demonstrated that recombinant human Gal-9 inhibit MLR in a dose-dependent manner, involving both Ca2+ influx and apoptosis in T cells. Next, we revealed that recombinant human Gal-9 significantly inhibit the progression of aGVHD in murine BM transplantation models. In conclusion, Gal-9 ameliorates aGVHD, possibly by inducing T-cell apoptosis, suggesting that gal-9 may be an attractive candidate for the treatment of aGVHD.
AB - Galectins comprise a family of animal lectins that differ in their affinity for β-galactosides. Galectin-9 (Gal-9) is a tandem-repeat-type galectin that was recently shown to function as a ligand for T-cell immunoglobin domain and mucin domain-3 (Tim-3) expressed on terminally differentiated CD4+ Th1 cells. Gal-9 modulates immune reactions, including the induction of apoptosis in Th1 cells. In this study, we investigated the effects of Gal-9 in murine models of acute GVH disease (aGVHD). First, we demonstrated that recombinant human Gal-9 inhibit MLR in a dose-dependent manner, involving both Ca2+ influx and apoptosis in T cells. Next, we revealed that recombinant human Gal-9 significantly inhibit the progression of aGVHD in murine BM transplantation models. In conclusion, Gal-9 ameliorates aGVHD, possibly by inducing T-cell apoptosis, suggesting that gal-9 may be an attractive candidate for the treatment of aGVHD.
UR - http://www.scopus.com/inward/record.url?scp=78650349323&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=78650349323&partnerID=8YFLogxK
U2 - 10.1002/eji.200939931
DO - 10.1002/eji.200939931
M3 - Article
C2 - 21182078
AN - SCOPUS:78650349323
VL - 41
SP - 67
EP - 75
JO - European Journal of Immunology
JF - European Journal of Immunology
SN - 0014-2980
IS - 1
ER -